Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

CRC selects water-soluble paclitaxel for phase I trial

July 2, 1999

CDK4-specific antisense oligodeoxynucleotides for inhibition of tumors

July 1, 1999

Coulter, SmithKline Beecham file BLA for Bexxar

July 1, 1999

5-Halo- or nitrate-substituted paclitaxels under study at Bristol-Myers Squibb

July 1, 1999

Alza's Doxil approved in U.S. for treatment of refractory ovarian cancer

July 1, 1999

Valentis moves IL-2 gene therapy to phase II

July 1, 1999

InKine files two patent applications relating to thrombospondin receptor

July 1, 1999

NCI initiates phase I trials with patient-specific cancer vaccines

July 1, 1999

Introgen Therapeutics receives milestone payment from RPR

July 1, 1999

Aronex reports responses in phase II trial of Atragen as treatment of NHL

June 30, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...